Immuron Limited · ASX:IMC
Immuron — Investor Presentation (February 2024)
13 slides from Immuron's investor presentation, Feb 8, 2024
Slide 1: Investor Webinar Presentation
Investor Webinar Presentation Melbourne, Australia, February 8, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Monsoon Communications In
Slide 2: For personal use only
risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform unde
Slide 3: Investor Presentation - Monsoon Communications
For personal use only INVESTOR PRESENTATION M O N S O O N C O M M U N I C AT I O N S 8 FEBRUARY, 2024 S t e v e n Ly d e a m o r e - C E O NASDAQ: IMRN ASX: IMC 1
Slide 4: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s For personal use onl
Slide 5: Revenue Generating with Strong Pipeline
REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only Financial Snapshot 30-Jun-23 31-Dec-23 S
Slide 6: Revenue Generating with Strong Pipeline - Pipeline Snapshot
REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only Pipeline Snapshot 30-Jun-23 31-Dec-23 Tr
Slide 7: Distribution Capability
DISTRIBUTION CAPABILITY Australia USA Canada Shandex Ontario, Canada For personal use only Distributes to all Retail Pharmacy provinces of Canada B2B Established E-commerce Developing Immuron Limited Vancouver, BC, Canada Key Commentary Australia • Retail network includes over 3,500 pharmacies RJW L
Slide 8: Traveller's Diarrhoea: Strong Sales Growth in a Billion Dollar Market
Traveller’s Diarrhoea (TD) STRONG SALES GROWTH IN Market is large and growing ~7% 3 CAGR A BILLION DOLLAR MARKET 3 Industry tailwinds For personal use only Travel picking up significantly following COVID lockdowns Frequent 30% - 70% of travelers experience TD 4 Australia Short term resident returns
Slide 9: Technology Platform for Gut Mediated Diseases
TECHNOLOGY PLATFORM FOR GUT MEDIATED DISEASES Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to F
Slide 10: Strong Pipeline with Near Term Milestones
STRONG PIPELINE WITH NEAR TERM MILESTONES Immuron’s Clinical Programs For personal use only Compound or Indication Phase Phase Phase Market brand name I II III Traveler’s IMM-124E Diarrhea ETEC Travelan® challenge Clostridioides difficile IMM-529 Infection & Recurrence Our Partners’ Clinical Program
Slide 11: Near Term Milestones Anticipated to Drive Value
NEAR TERM MILESTONES ANTICIPATED TO DRIVE VALUE 2H 2022 1H 2023 2H 2023 1H 2024 2H 2024 For personal use only • FDA IND1 approved for • IRB Approval4 • 100% of patients enrolled • Topline results for IMM- • Clinical Study Report single daily dose IMM- • Initiated IMM-124E ETEC2 • Completion of In-pa
Slide 12: Scientific References
SCIENTIFIC REFERENCES Travelan® (IMM-124E) Travelan® has been shown to reduce both the incidence and severity of ETEC-induced diarrhea in up to 90% Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: For personal use only of volunteers 10.3109/00365521.2011.574726 Clinical Evaluation of
Slide 13: Steven Lydeamore, Chief Executive Officer
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 11